Julia Snider, PhD, from Precision Health Economics, San Francisco, CA, talks to us about the social value of the CAR T-cell product tisagenlecleucel for the treatment of relapsed or refractory pedatric acute lymphoblastic leukemia (ALL) in the United States. Dr Snider discusses the various social and economical factors that were analyzed as part of the study, commenting on the novel strategies that have been considered in order to managed these costs, as well as the consequence of treatment delays in ALL. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
What is the social value of CAR T-cell therapy in ALL?
